Skip to main content

Table 4 Base case utility and cost breakdown

From: Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States

 

Cabozantinib

BSC

 

Utilities

 

Utility gain

Utility gain

Incremental utility

Stable LY

0.646

0.341

0.305

Progressive LY

0.505

0.632

−0.127

Total

1.151

0.973

0.178

Stable QALY

0.491

0.259

0.232

Progressive QALY

0.343

0.429

−0.086

Total

0.834

0.698

0.146

 

Costs in $ (%a)

Costs in $ (%a)

Incremental costs (%a)

Costs Germany

 Cabozantinib

53,018 (93.6)

0 (0.0)

53,018 (97.2)

 Adverse events

1607 (2.8)

375 (18.2)

1232 (2.3)

 Consultation

513 (0.9)

434 (21.0)

69 (0.1)

 Laboratory

202 (0.4)

173 (8.4)

29 (< 0.1)

 Imaging

1281 (2.3)

1083 (52.5)

198 (0.4)

 Total

56,621 (100.0)

2064 (100.0)

54,556 (100.0)

Costs United States

 Cabozantinib

167,288 (94.6)

0 (0.0)

167,288 (96.8)

 Adverse events

6030 (3.8)

1075 (56.2)

4955 (2.9)

 Consultation

1075 (0.6)

914 (43.8)

161 (0.1)

 Laboratory

868 (0.3)

751 (0.0)

117 (0.1)

 Imaging

2236 (0.7)

1890 (0.0)

346 (0.2)

 Total

177,496 (100.0)

4630 (100.0)

172,866 (100.0)

  1. BSC best supportive care, LY life years, QALY quality-adjusted life years. Total values may be affected by rounding errors. a % of total